Therefore, these studies suggest that the inhibition of Shp1 in effector T-cells could be a therapeutic strategy to be used alone or in combination with other immunomodulating strategies (e.g., PD-1 or CTLA-4 inhibition) and amenable to increase therapeutic activity of the tumor-specific T-cells. This evidence concerns the gene PDCD1 and neoplasm.